The effect of chemotherapy on coagulation in patients with locally advanced or metastasized pancreatic cancer
Completed
- Conditions
- blood clottingcoagulation1002765610014523
- Registration Number
- NL-OMON41433
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
• Ductal adenocarcinoma of the pancreas confirmed by histology or cytology
• Locally advanced or metastasized disease
• Planned for first line FOLFIRINOX chemotherapy with or without CCX872-B
• Chemotherapy naïve
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• 18 years of age or older
• Fully capable of making health related decisions
• Written informed consent
Exclusion Criteria
• Current prophylactic or therapeutic anticoagulant therapy
• Current use of anti-inflammatory drugs
• Renal insufficiency with estimated glomerular filtration rate < 30 mL/min before start of chemotherapy
• Venous thromboembolism < 3 months prior to chemotherapy
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- Increase of procoagulant microparticles during chemotherapy<br /><br>- Source of procoagulant microparticles</p><br>
- Secondary Outcome Measures
Name Time Method <p>- Levels of coagulation markers during chemotherapy<br /><br>- Levels of inflammation markers during chemotherapy<br /><br>- Association between inflammation and coagulation</p><br>